On- versus off-label use of drug-eluting coronary stents in clinical practice (Report from the American College of Cardiology National Cardiovascular Data Registry [NCDR])

被引:68
作者
Rao, Sunil V. [1 ]
Shaw, Richard E.
Brindis, Ralph G.
Klein, Lloyd W.
Weintraub, William S.
Peterson, Eric D.
机构
[1] Duke Univ, Clin Res Inst, Durham, NC 27706 USA
[2] Sutter Pacific Heart Ctr, San Francisco, CA USA
[3] Oakland Kaiser Hosp, Div Cardiol, Oakland, CA USA
[4] Rush Univ, Med Ctr, Div Cardiol, Chicago, IL 60612 USA
[5] Christiana Care Hlth Syst, Newark, DE USA
关键词
D O I
10.1016/j.amjcard.2005.11.081
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Limited data are available on the off-label use of drug-eluting stents (DESs) in clinical practice. We used data from the American College of Cardiology National Cardiovascular Data Registry to describe the rates and outcomes of DES use in 4 common off-label situations: ST-elevation myocardial infarction, in-stent restenosis, coronary artery bypass grafts, and chronic total occlusions. The rates of in-hospital adverse events for each off-label situation were determined and compared with the expected rates calculated from a validated model. From approval of DESs to the end of 2004, a total of 408,033 procedures involved placement of a DES. The use of DESs increased from 19.7% at the start of the study to 78.2% by the end of fourth quarter of 2004. Off-label use of DESs occurred in 24.1% of procedures. The rates of in-hospital adverse events with DES use in ST-elevation myocardial infarction, in-stent restenosis, coronary artery bypass grafting, and chronic total occlusions were lower than,expected from the validated model. In conclusion, off-label use of DESs is common and is associated with a low rate of short-term adverse events. Randomized clinical trials are needed to confirm the efficacy of DESs in these clinical and angiographic settings. These data also highlight the importance of multicenter registries in tracking new technologies. (c) 2006 Elsevier Inc. All rights reserved.
引用
收藏
页码:1478 / 1481
页数:4
相关论文
共 19 条
[1]   Use of drug-eluting stents for the treatment of in-stent restenosis in routine clinical practice [J].
Belardi, JA ;
Cura, F ;
Albertal, M ;
Padilla, L ;
Solioz, G ;
Balino, PP ;
Pascua, JA ;
Fava, C ;
Berrocal, D ;
Mendiz, O ;
Grinfeld, L .
CORONARY ARTERY DISEASE, 2005, 16 (05) :327-330
[2]   Identification of variables needed to risk adjust outcomes of coronary interventions: Evidence-based guidelines for efficient data collection [J].
Block, PC ;
Peterson, EC ;
Krone, R ;
Kesler, K ;
Hannan, E ;
O'Connor, GT ;
Detre, K .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (01) :275-282
[3]  
Brindis R G, 2001, J Am Coll Cardiol, V37, P2240, DOI 10.1016/S0735-1097(01)01372-9
[4]  
GARDNER S, 2005, FINAL REPORT STUDY E, P1
[5]   Treatment of saphenous vein graft lesions with drug-eluting stents - Immediate and midterm outcome [J].
Ge, L ;
Iakovou, I ;
Sangiorgi, GM ;
Chieffo, A ;
Melzi, G ;
Cosgrave, J ;
Montorfano, M ;
Michev, I ;
Airoldi, F ;
Carlino, M ;
Corvaja, N ;
Colombo, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (07) :989-994
[6]   Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions [J].
Hoye, A ;
Tanabe, K ;
Lemos, PA ;
Aoki, J ;
Saia, F ;
Arampatzis, C ;
Degertekin, M ;
Hofma, SH ;
Sianos, G ;
McFadden, E ;
van der Giessen, WJ ;
Smits, PC ;
de Feyter, PJ ;
van Domburg, RT ;
Serruys, PW .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (11) :1954-1958
[7]  
Hoye Angela, 2004, J Invasive Cardiol, V16, P230
[8]   Short- and long-term clinical benefit of sirolimus-eluting Stents compared to conventional bare stents for patients with acute myocardial infarction [J].
Lemos, PA ;
Saia, F ;
Hofma, SH ;
Daemen, J ;
Ong, ATL ;
Arampatzis, CA ;
Hoye, A ;
McFadden, E ;
Sianos, G ;
Smits, PC ;
van der Giessen, WJ ;
de Feyter, P ;
van Domburg, RT ;
Serruys, PW .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (04) :704-708
[9]   Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world" -: The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Registry [J].
Lemos, PA ;
Serruys, PW ;
van Domburg, RT ;
Saia, F ;
Arampatzis, CA ;
Hoye, A ;
Degertekin, M ;
Tanabe, K ;
Daemen, J ;
Liu, TKK ;
McFadden, E ;
Sianos, G ;
Hofma, SH ;
Smits, PC ;
van der Giessen, WJ ;
de Feyter, PJ .
CIRCULATION, 2004, 109 (02) :190-195
[10]   Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy [J].
McFadden, EP ;
Stabile, E ;
Regar, E ;
Cheneau, E ;
Ong, ATL ;
Kinnaird, T ;
Suddath, WO ;
Weissman, NJ ;
Torguson, R ;
Kent, KM ;
Pichard, AD ;
Satler, LF ;
Waksman, R ;
Serruys, PW .
LANCET, 2004, 364 (9444) :1519-1521